Top 10 GLP-1 & Cancer History Questions from Reddit, Answered

Question 1

Does the GLP-1 boxed warning actually apply to me if I had thyroid cancer but not medullary?

Accepted Answer

The shared boxed warning on Wegovy, Zepbound, Ozempic, Mounjaro, Saxenda and Trulicity contraindicates use in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), not all thyroid cancer. MTC is a specific calcitonin-producing parafollicular C-cell tumor that accounts for roughly 1-2% of thyroid cancers. The much more common subtypes (papillary, follicular and Hürthle cell) arise from different cells and are not the subject of the rodent C-cell signal that drove the warning. A 2024 narrative review in Thyroid concluded that human evidence for an MTC signal from GLP-1 receptor agonists remains absent and that the boxed warning rests on rodent biology rather than human postmarketing data (Espinosa De Ycaza 2024, PMID 38343381). Practical reality: papillary, follicular and Hürthle cell survivors who have completed treatment routinely receive GLP-1s after oncology and endocrinology clearance, and the labels do not exclude them. Survivors should confirm their tumor pathology, share that with the prescriber, and continue routine surveillance. None of this is medical advice and the decision belongs with the oncology and endocrinology team.

Question 2

I'm a breast cancer survivor on tamoxifen or an aromatase inhibitor. Is Wegovy or Zepbound safe?

Accepted Answer

The published safety literature does not show a consistent breast cancer signal for GLP-1 receptor agonists, and the labels do not contraindicate use in breast cancer survivors or in patients on endocrine therapy. A 2021 systematic review and meta-analysis in the Journal of Clinical Endocrinology and Metabolism pooled randomized trials of GLP-1 receptor agonists and found no statistically significant increase in breast cancer incidence versus comparators (Piccoli 2021, PMID 33248445). A 2025 meta-analysis of randomized trials in Diabetes Obesity and Metabolism examining cancer outcomes across the GLP-1 class similarly found no significant overall cancer signal, including for breast cancer (Silverii 2025, PMID 40437949). The 2024 JAMA Network Open cohort of patients with type 2 diabetes treated with GLP-1 receptor agonists examined 13 obesity-associated cancers including post-menopausal breast cancer and found no elevated risk versus insulin comparators (Wang 2024, PMID 38967919). Tamoxifen and aromatase inhibitors have no published pharmacokinetic interaction with semaglutide or tirzepatide. Survivorship care including ongoing mammography and oncology follow-up should continue unchanged on a GLP-1. None of this is medical advice and the decision belongs with the oncologist.

Question 3

I have a family history of medullary thyroid cancer or MEN 2. Can I take Zepbound or Wegovy at all?

Accepted Answer

No. Personal or family history of MTC or MEN 2 is the only absolute cancer-related contraindication in the prescribing label for all of Wegovy, Zepbound, Ozempic, Mounjaro, Saxenda and Trulicity, and it applies regardless of whether you yourself have been tested or diagnosed. The contraindication comes from rodent carcinogenicity studies where semaglutide, liraglutide and tirzepatide produced dose-dependent thyroid C-cell tumors, and from the principle that patients with MEN 2 have a known germline RET mutation that already predisposes the C-cell lineage to malignant transformation. The 2016 LEADER trial of liraglutide for cardiovascular outcomes excluded patients with personal or family history of MTC or MEN 2 (Marso 2016, PMID 27295427), and every subsequent obesity trial (STEP-1, SURMOUNT-1, SELECT) has retained that exclusion (Wilding 2021 PMID 33567185; Jastreboff 2022 PMID 35658024; Lincoff 2023 PMID 37952131). Patients on the GLP-1 subreddits sometimes discover an MEN 2 family link after starting therapy; the published guidance is to stop the drug, obtain genetic counseling, and discuss alternatives with endocrinology. None of this is medical advice.

Question 4

Did GLP-1s actually cause thyroid cancer in humans, or only in lab rats?

Accepted Answer

The boxed warning rests on rodent biology, not human outcomes data. In rodent carcinogenicity studies, semaglutide, liraglutide and tirzepatide produced dose-dependent and exposure-duration-dependent thyroid C-cell tumors. Whether that signal translates to humans is unknown and has been studied across multiple large datasets. A 2023 French nested case-control study by Bezin and colleagues using national health insurance data initially reported an elevated odds ratio for thyroid cancer (including all subtypes) with 1-3 years of GLP-1 exposure (Bezin 2023, PMID 36356111). The study was followed by a much larger 2024 Scandinavian cohort using Danish, Norwegian and Swedish national registries that found no overall increased thyroid cancer risk for GLP-1 users versus DPP-4 inhibitor comparators (Pasternak 2024, PMID 38683947). The 2024 Thyroid narrative review concluded the human MTC signal remains absent and that the broader thyroid cancer signal across studies is inconsistent and may reflect surveillance bias rather than causation (Espinosa De Ycaza 2024, PMID 38343381). The 2025 RCT meta-analysis (Silverii 2025, PMID 40437949) found no significant cancer increase across the GLP-1 class. None of this is medical advice.

Question 5

Does the pancreatic cancer scare from years ago still apply to Ozempic and Wegovy?

Accepted Answer

The pancreatic cancer concern dates to early observational reports with exenatide and sitagliptin in the early 2010s and has been substantially walked back by larger and more recent data. The 2023 Mendelian randomization analysis in Diabetologia using genetic variants as proxies for lifetime GLP-1 receptor activation found no causal association with pancreatic cancer or with several other cancers (Yarmolinsky 2023, PMID 37171501). The 2024 JAMA Network Open cohort of 1.6 million patients with type 2 diabetes treated with GLP-1 receptor agonists found no elevated risk of pancreatic cancer compared with insulin, and a reduced risk for several obesity-associated cancers (Wang 2024, PMID 38967919). The 2025 meta-analysis of cancer outcomes across randomized GLP-1 trials similarly found no significant pancreatic cancer signal (Silverii 2025, PMID 40437949). Pancreatitis itself remains a documented but uncommon adverse event in the prescribing label, and patients with a personal history of pancreatitis are usually counseled to discuss the risk-benefit with their prescriber. The chronic-pancreatic-cancer signal that circulated on Reddit in the mid 2010s is not supported by the current evidence base. None of this is medical advice.

Question 6

I'm a colorectal cancer survivor in remission. Can I take a GLP-1 to help with weight regain?

Accepted Answer

Colorectal cancer history is not a contraindication in the Wegovy, Zepbound, Ozempic, Mounjaro, Saxenda or Trulicity labels, and the pooled human evidence does not show a colorectal cancer signal. The 2024 JAMA Network Open cohort of 1.6 million type 2 diabetes patients treated with GLP-1 receptor agonists examined colorectal cancer among the 13 obesity-associated cancers and found no elevated risk versus insulin comparators, with a reduced risk signal in several analyses (Wang 2024, PMID 38967919). The 2023 Mendelian randomization analysis in Diabetologia using genetic proxies for GLP-1 target perturbation found no causal increased risk of colorectal cancer (Yarmolinsky 2023, PMID 37171501). The 2025 meta-analysis of randomized GLP-1 trials similarly reported no significant colorectal cancer increase (Silverii 2025, PMID 40437949). Practical considerations for survivors: continue scheduled colonoscopy surveillance per oncology and gastroenterology guidance; discuss timing if abdominal symptoms emerge on the GLP-1 since they can confound surveillance imaging; and disclose the cancer history during pre-procedure intake. None of this is medical advice and survivorship management belongs with the oncology team.

Question 7

Are GLP-1s actually protective against any cancers in obesity?

Accepted Answer

The pooled evidence is suggestive of a reduced risk for several obesity-associated cancers, but the effect is most likely mediated by weight loss rather than a direct drug-specific anticancer mechanism. The 2024 JAMA Network Open cohort of 1.6 million patients with type 2 diabetes treated with GLP-1 receptor agonists found statistically reduced incidence of several of the 13 obesity-associated cancers compared with insulin comparators, including gallbladder, meningioma, pancreatic, hepatocellular, ovarian, and colorectal cancer in subgroup analyses (Wang 2024, PMID 38967919). Long-term follow-up data from the SELECT trial of semaglutide in obesity without diabetes documented sustained weight loss of roughly 10% at 4 years (Ryan 2024, PMID 38740993), and weight loss of that magnitude has long been associated in epidemiologic studies with reductions in obesity-attributable cancers. The 2025 meta-analysis of randomized GLP-1 trials reported no significant overall cancer increase and signals consistent with possible reductions in some sites (Silverii 2025, PMID 40437949). The mechanism is likely indirect: less adiposity, lower circulating insulin and IGF-1, lower inflammation. None of this is medical advice.

Question 8

Should I worry about thyroid nodules I had before starting a GLP-1?

Accepted Answer

Pre-existing thyroid nodules are extremely common (detected in roughly half of adults on careful ultrasound) and are not in themselves a label contraindication for Wegovy, Zepbound, Ozempic, Mounjaro, Saxenda or Trulicity. The contraindication is specifically personal or family history of medullary thyroid carcinoma or MEN 2. Most thyroid nodules are benign colloid nodules or follicular adenomas, and standard endocrinology guidance is to characterize them by ultrasound (size, composition, echogenicity, margins, vascularity) and selectively biopsy those that meet size and risk-feature thresholds. The 2024 Thyroid narrative review noted that the human MTC signal from GLP-1 receptor agonists remains absent and emphasized that nodule-bearing patients should not be reflexively excluded from therapy (Espinosa De Ycaza 2024, PMID 38343381). The 2024 Scandinavian cohort study found no overall thyroid cancer signal in GLP-1 users compared with DPP-4 inhibitor users (Pasternak 2024, PMID 38683947). Practical pattern: disclose any known nodule history, share the most recent ultrasound report and TSH and calcitonin if measured, and let the prescriber and endocrinologist decide on surveillance. None of this is medical advice.

Question 9

Should I hold my GLP-1 before a screening colonoscopy or staging endoscopy?

Accepted Answer

Yes, in most current practice, especially for survivors on surveillance schedules. The 2024 JAMA Surgery prospective cohort by Sen and colleagues found GLP-1 users had a roughly 5.6-fold higher prevalence of increased residual gastric contents on point-of-care ultrasound before anesthesia compared with non-GLP-1 controls (Sen 2024, PMID 38446466). For cancer survivors on regular colonoscopy or upper endoscopy schedules, retained gastric contents matter for two reasons: they elevate aspiration risk during sedation, and they can obscure mucosal visualization. Current professional society guidance varies but the common practical pattern is to hold weekly GLP-1 receptor agonists for the full week of the procedure (skip the dose 5-7 days prior) and follow an extended clear-liquid fast the day before. The anesthesia team and endoscopist make the final call based on individual fasting and procedure type. Always disclose GLP-1 use during pre-procedure intake, especially on cancer-survivorship surveillance, because the imaging quality affects the surveillance interval. None of this is medical advice.

Question 10

Will my oncologist sign off on a GLP-1 if I'm still in active treatment or recent remission?

Accepted Answer

It depends on the cancer type, current treatment phase, and oncologist judgment, and there is no across-the-board oncology contraindication beyond the MTC and MEN 2 label exclusion. Active chemotherapy, immunotherapy or radiation often add nausea, vomiting, anorexia and fatigue that overlap with the early GLP-1 titration phase, and many oncologists prefer to defer GLP-1 initiation until the patient is post-acute treatment and stable. Active treatment that involves significant unintentional weight loss is generally a contraindication for an appetite-suppressing drug regardless of cancer type. For patients in remission, the consideration shifts to weight regain risk and obesity-related comorbidity management, and the published evidence does not show an across-the-board cancer-recurrence signal: the 2024 JAMA Network Open 13-cancer cohort found no elevated risk and reduced risk for several sites (Wang 2024, PMID 38967919), and the 2025 RCT meta-analysis found no significant cancer increase (Silverii 2025, PMID 40437949). Document the cancer history in your prescriber intake, share recent oncology notes, and ask the oncologist to communicate directly with the GLP-1 prescriber when feasible. None of this is medical advice.

Questions and answers